Physician profile
Aida Capo
NPI 1235239369
$8,543.74
in general payments reported to CMS, 2019-2025
29 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $483 · 2021: $802 · 2022: $1,261 · 2023: $1,378 · 2024: $1,353 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,560 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,559.60 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,841.59 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,753.88 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Mylan Specialty L.P. | $1,155.74 | 2019-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.04 | 2019-2025 | Ofev, Jascayd |
| Philips North America LLC | $511.67 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genzyme Corporation | $353.28 | 2019-2025 | |
| Viatris Specialty LLC | $341.46 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $312.55 | 2019-2025 | Dupixent |
| Inspire Medical Systems, INC. | $283.70 | 2022-2024 | Inspire |
| Genentech USA, INC. | $212.66 | 2019-2022 | |
| Insmed, INC. | $209.53 | 2020-2025 | Arikayce, Brinsupri |
| Sanofi-Aventis U.S. LLC | $164.98 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $149.40 | 2020-2025 | Acthar |
| Verona Pharma, INC. | $102.52 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $82.55 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $68.99 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $64.58 | 2021-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $60.18 | 2019-2023 | |
| Grifols USA, LLC | $48.03 | 2019-2025 | Prolastin-C Liquid |
| Optinose US, INC. | $40.25 | 2024-2025 | |
| Baxter Healthcare | $35.00 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Electromed, INC. | $21.97 | 2019 | |
| Amgen INC. | $17.25 | 2025 | Tezspire |
| Azurity Pharmaceuticals, INC. | $16.28 | 2025 | Horizant |
| Mallinckrodt Enterprises LLC | $14.98 | 2019 | |
| Pfizer INC. | $13.79 | 2021 | |
| Gilead Sciences, INC. | $13.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.79 | 2022 | |
| Shire North American Group INC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Capo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.